Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study

Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study

Axitinib demonstrated clinical activity and safety in treatment-naïve Japanese patients with metastatic renal cell carcinoma. Multivariate analyses identified potential predictive factors for axitinib efficacy in first-line metastatic renal cell carcinoma.

Bibliographic Details
Main Authors: Tomita, Yoshihiko, Fukasawa, Satoshi, Oya, Mototsugu, Uemura, Hirotsugu, Shinohara, Nobuo, Habuchi, Tomonori, Rini, Brian I., Chen, Ying, Bair, Angel H., Ozono, Seiichiro, Naito, Seiji, Akaza, Hideyuki
Format: Online
Language:English
Published: Oxford University Press 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091032/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091032/

Similar Items